(Total Views: 520)
Posted On: 10/21/2020 3:11:57 PM
Post# of 155592
Their trial is blinded with placebo
The issue is that it's a small trial, 144 patients total (the interim is at 102). They'll have a tough time hitting the primary endpoint of mortality but going by their eIND results they should do well on their other primary endpoint, which is PaO2:FiO2 ratio.
It's a very promising drug for covid but with 2.25 billion shares outstanding and no real other indication beyond covid, as an investment it offers a different kind of risk.
The issue is that it's a small trial, 144 patients total (the interim is at 102). They'll have a tough time hitting the primary endpoint of mortality but going by their eIND results they should do well on their other primary endpoint, which is PaO2:FiO2 ratio.
It's a very promising drug for covid but with 2.25 billion shares outstanding and no real other indication beyond covid, as an investment it offers a different kind of risk.
(2)
(0)
